Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2017-2021


◆タイトル:Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥364,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。





About Hematopoietic Stem Cells Transplantation (HSCT)HSCT is the most widely used stem-cell therapy, where blood from umbilical cord is used. Research is being undertaken to discover various sources (such as cord blood cells, bone marrow, and peripheral blood cells) of hematopoietic stem cells to treat various disorders like hematological malignancies, blood related disorders (leukemia and lymphoma), neurodegenerative diseases and conditions such as heart disease, diabetes, and other conditions.
Stem-cell therapy has become controversial after developments in isolating and culturing of embryonic stem cells. Somatic cell nuclear transfer is the technique used in embryonic stem cell research to create stem cells and induced pluripotent stem cells. This controversy is related to abortion policies and human cloning. However, the changing regulatory landscape in countries like the US and Japan may help to accelerate the clinical trials.

Technavio’s analysts forecast the global hematopoietic stem cells transplantation (HSCT) market to grow at a CAGR of 5.75% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global hematopoietic stem cells transplantation (HSCT) market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of hematopoietic stem cells transplantation (HSCT).

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AllCells
• Lonza
• Merck
• Sanofi

[Other prominent vendors]
• Athersys
• Beike Biotechnology
• BioTime
• bluebird bio
• Caladrius
• Cellular Biomedicine Group
• Cellular Dynamics International (a subsidiary of Fujifilm)
• Cesca Therapeutics
• CHA Biotech
• Gamida Cell
• Global Stem Cells Group
• Hemostemix
• Histocell
• Mesoblast
• TiGenix
• Translational Biosciences (a subsidiary of Medistem Panama)

[Market driver]
• Rising number of HSCT
• For a full, detailed list, view our report

[Market challenge]
• High cost of HSCT
• For a full, detailed list, view our report

[Market trend]
• Growing demand for personalized medicine
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents.
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: HSCT: An overview
• Hematopoietic stem cell transplantation
• Source of hematopoietic cells
• Types of transplant
• The HSCT procedure

PART 06: Pipeline

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Market segmentation by therapeutic application
• HL
• MM
• Others

PART 09: Market segmentation by transplant
• Global autologous HSCT market
• Global allogenic HSCT market

PART 10: Geographical segmentation
• HSCT market in EMEA
• HSCT market in Americas
• HSCT market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges
• Market drivers
• Market challenges

PART 13: Market trends
• Growing demand for personalized medicine
• Decreasing morbidity and mortality rate
• Advent of cord blood banking
• Increasing focus in RIC regimen

PART 14: Vendor landscape
• Competitive scenario

PART 15: Key vendor analysis
• AllCells
• Lonza
• Merck
• Sanofi
• Other prominent vendors

PART 16: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Developments in stem cell research
Exhibit 02: Global HSCT market snapshot
Exhibit 03: History of HSCT
Exhibit 04: HSCT sources
Exhibit 05: Types of transplant
Exhibit 06: Pipeline snapshot based on vendors
Exhibit 07: Pipeline snapshot based on type of intervention
Exhibit 08: Pipeline snapshot based on different-phases
Exhibit 09: Pipeline landscape
Exhibit 10: Purpose of trial
Exhibit 11: Global HSCT market snapshot 2016
Exhibit 12: Global HSCT market 2016-2021 ($ millions)
Exhibit 13: Opportunity analysis in global HSCT market
Exhibit 14: Five forces analysis
Exhibit 15: Global HSCT market segmentation by therapeutic application
Exhibit 16: Global HSCT market share by therapeutic application
Exhibit 17: HSCT for other diseases
Exhibit 18: Global HSCT market segmentation by transplant type
Exhibit 19: Global HSCT market share by transplant type 2016
Exhibit 20: Global autologous HSCT market 2016-2021 ($ millions)
Exhibit 21: Opportunity analysis of global autologous HSCT market
Exhibit 22: Global allogenic HSCT market 2016-2021 ($ millions)
Exhibit 23: Opportunity analysis of global allogeneic HSCT market
Exhibit 24: Global HSCT market by geography 2016 and 2021
Exhibit 25: Global HSCT market revenue by geography 2016-2021 ($ millions)
Exhibit 26: Global HSCT market by geography 2016-2021 (%)
Exhibit 27: Market scenario in EMEA
Exhibit 28: HSCT market in EMEA 2016-2021 ($ millions)
Exhibit 29: Market scenario in Americas
Exhibit 30: HSCT market in Americas 2016-2021 ($ millions)
Exhibit 31: Market scenario in APAC
Exhibit 32: HSCT market in APAC 2016-2021 ($ millions)
Exhibit 33: Snapshot of transplant scenario from 1984-2007
Exhibit 34: Funding for stem cell research 2013-2018
Exhibit 35: Details of European Commission funding
Exhibit 36: Long-term complications associated with HSCT
Exhibit 37: Symptoms of GvHD
Exhibit 38: Risk of mortality in age-matched general population and HSCT patient with two years after allogenic transplant
Exhibit 39: Benefits of using RIC
Exhibit 40: Competitive structure analysis of global HSCT market 2016
Exhibit 41: AllCells: Key highlights
Exhibit 42: AllCells: Strength assessment
Exhibit 43: AllCells: Strategy assessment
Exhibit 44: AllCells: Opportunity assessment
Exhibit 45: Lonza: Key highlights
Exhibit 46: Lonza: Strength assessment
Exhibit 47: Lonza: Strategy assessment
Exhibit 48: Lonza: Opportunity assessment
Exhibit 49: Merck: Key highlights
Exhibit 50: Merck: Strength assessment
Exhibit 51: Merck: Strategy assessment
Exhibit 52: Merck: Opportunity assessment
Exhibit 53: Sanofi: Key highlights
Exhibit 54: Sanofi: Strength assessment
Exhibit 55: Sanofi: Strategy assessment
Exhibit 56: Sanofi: Opportunity assessment


AllCells, Lonza, Merck, Sanofi, Athersys, Beike Biotechnology, BioTime, bluebird bio, Caladrius, Cellular Biomedicine Group, Cellular Dynamics International (a subsidiary of Fujifilm), Cesca Therapeutics, CHA Biotech, CORESTEM, Gamida Cell, Global Stem Cells Group, Hemostemix, Histocell, Mesoblast, TiGenix, and Translational Biosciences (a subsidiary of Medistem Panama).